Labcorp Holdings INC Form 4 insider transactions

Director Paul Rothman reports the vesting of restricted stock units and acquisition of Labcorp shares on February 6, 2025.

Director Dwight Gary Gilliland reports the vesting of restricted stock units into Labcorp Holdings Inc. common stock.

Labcorp director Kerrii B. Anderson sold 1,000 shares of common stock at $235 per share on January 7, 2025, under a pre-arranged 10b5-1 trading plan.

Labcorp's Chief Financial Officer, Julia Wang, has acquired 8,100 stock options and 2,680 restricted stock units, according to a recent SEC filing.

Labcorp's Executive Vice President, Glenn Eisenberg, exercised stock options and sold shares on December 2, 2024, according to a recent SEC filing.

Labcorp director Dwight Gary Gilliland sold 1,000 shares of common stock at $241 per share on December 2, 2024.

Labcorp's EVP, Chief Marketing Officer, Amy B. Summy, exercised stock options and sold a portion of her holdings on November 22, 2024.

Labcorp's Executive Vice President and Chief Legal Officer, Sandra D. van der Vaart, sold 1,000 shares of common stock on November 21, 2024.

Labcorp's CEO, Adam Schechter, sold 6,189 shares of common stock at $243.47 per share on November 11, 2024, under a pre-arranged 10b5-1 trading plan.

Akinbolade Oyegunwa, EVP, CIO & CTO of Labcorp Holdings Inc., reported the acquisition of 1,110 restricted stock units on November 1, 2024.

Megan D. Bailey, EVP, Pres, Central Labs & Intl at Labcorp Holdings Inc., reports the acquisition of 1,110 Restricted Stock Units on November 1, 2024.

Kerrii B. Anderson, a director at Labcorp Holdings Inc., sold 1,000 shares of common stock at $230 per share on October 24, 2024, under a pre-arranged 10b5-1 trading plan.

Sandra D. van der Vaart, EVP and Chief Legal Officer of Labcorp Holdings Inc., sold 2,000 shares of common stock on August 19, 2024.

Labcorp's CFO, Glenn A. Eisenberg, executed multiple sales of common stock on August 15, 2024, reducing his holdings.

Director Kerrii B. Anderson reported the sale of Labcorp Holdings Inc. (LH) common stock on August 7th and 8th, 2024, according to a Form 4 filing with the SEC.

Lance Berberian, EVP, CIO & CTO of Labcorp Holdings Inc., sold 12,093 shares of common stock on August 5, 2024, at weighted average prices of $229.785 and $228.9485 per share.

Director Paul Rothman reports the vesting and disposal of 717 Restricted Stock Units of Labcorp Holdings Inc. on June 6, 2024.

Sandra D. van der Vaart, EVP, Chief Legal Officer of Laboratory Corp of America Holdings, sold a portion of her common stock holdings on May 14, 2024.

Kerrii B. Anderson, a director of Laboratory Corp of America Holdings (LH), sold 500 shares of common stock in two separate transactions on April 30, 2024, and May 2, 2024.

Glenn Eisenberg, CFO of Laboratory Corporation of America Holdings, reports the acquisition and disposal of common stock and performance share units on April 30, 2024.

Peter J. Wilkinson, SVP, Chief Accounting Officer of Laboratory Corp of America Holdings, reports the sale of 2,439 shares of common stock at a weighted average price of $204.329 per share on April 29, 2024.

Glenn Eisenberg, CFO of Laboratory Corporation of America Holdings, reports the vesting and subsequent disposal of shares to cover tax obligations on April 15, 2024.

Mark S. Schroeder, EVP, Pres Diagnostics & COO of Laboratory Corp of America Holdings, sold 6,477 shares of common stock at a price of $217.29 per share on April 1, 2024, according to a Form 4 filing with the SEC.

Amy B. Summy, EVP, Chief Marketing Officer of Laboratory Corp of America Holdings, sold 3,500 shares of common stock on April 1, 2024, at a price of $217.29 per share.

Megan D. Bailey, EVP, Chief Strategy Officer of Laboratory Corporation of America Holdings, reports the vesting of restricted stock units and subsequent stock withholding for tax obligations.

Sandra van der Vaart, EVP and Chief Legal Officer of Laboratory Corporation of America Holdings (Labcorp), reports the vesting of restricted stock units and subsequent stock sales to cover tax obligations.

Brian J. Caveney, EVP, President of ED, CMO & CSO at Laboratory Corporation of America Holdings (Labcorp), reports the vesting of restricted stock units and subsequent tax withholding.

EVP, Pres Diagnostics & COO Mark S. Schroeder reports the vesting of restricted stock units and subsequent stock withholding for tax obligations.

Adam Schechter, President and CEO of Laboratory Corporation of America Holdings, reports the exercise of restricted stock units and subsequent disposal of shares to cover tax obligations.

Jonathan P. DiVincenzo, EVP, Pres, Central Labs & Intl at Laboratory Corp of America Holdings, reports the vesting and subsequent transactions of restricted stock units.